{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:51:52Z","timestamp":1791481912636,"version":"4.3.4"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260463"],"award-info":[{"award-number":["82260463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007471","name":"Applied Basic Research Foundation of Yunnan Province","doi-asserted-by":"publisher","award":["202401AT070159"],"award-info":[{"award-number":["202401AT070159"]}],"id":[{"id":"10.13039\/100007471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118500","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:45:26Z","timestamp":1790462726000},"page":"118500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["\u03b1,\u03b2-Unsaturated carbonyl-based anticancer agents targeting cysteine residues"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-981X","authenticated-orcid":false,"given":"Chuan-Huizi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nini","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangwei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchem.2479","article-title":"Counting on natural products for drug design","volume":"8","author":"Rodrigues","year":"2016","journal-title":"Nat. Chem."},{"key":"10.1016\/j.bcp.2026.118500_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118280","article-title":"Natural products harboring Michael receptors: A focus on targeting cancer stem cells","volume":"302","author":"Liu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118500_b0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tox.2019.02.005","article-title":"Mechanisms of soft and hard electrophile toxicities","volume":"418","author":"LoPachin","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/j.bcp.2026.118500_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2021.03.040","article-title":"Kinetic assessment of Michael addition reactions of alpha, beta-unsaturated carbonyl compounds to amino acid and protein thiols","volume":"169","author":"Sauerland","year":"2021","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.bcp.2026.118500_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0009-2797(02)00178-3","article-title":"Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal","volume":"143\u2013144","author":"Doorn","year":"2003","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.bcp.2026.118500_b0030","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jmb.2010.09.027","article-title":"Cysteine function governs its conservation and degeneration and restricts its utilization on protein surfaces","volume":"404","author":"Marino","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118500_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102435","article-title":"A new era of cysteine proteomics - technological advances in thiol biology","volume":"79","author":"Burger","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00726","article-title":"Profiling the landscape of cysteine posttranslational modifications in brain aging and neurodegeneration","volume":"22","author":"Filipovic","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/ars.2010.3376","article-title":"Cysteine-based redox switches in enzymes","volume":"14","author":"Klomsiri","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcp.2026.118500_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103355","article-title":"Sensor systems of KEAP1 uniquely detecting oxidative and electrophilic stresses separately In vivo","volume":"77","author":"Sato","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.118500_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2026.112502","article-title":"PPT1 regulates mitochondrial redox by depalmitoylating PRDX3","volume":"143","author":"Zhu","year":"2026","journal-title":"Cell. Signal."},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0060","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14728222.2023.2266571","article-title":"Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment","volume":"27","author":"Carreira","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"13","key":"10.1016\/j.bcp.2026.118500_b0065","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1089\/ars.2012.5007","article-title":"Glutaredoxins in thiol\/disulfide exchange","volume":"18","author":"Lillig","year":"2013","journal-title":"Antioxid. Redox Signal."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110557","article-title":"10 things you wish you knew about inflammatory caspases: A holistic review of their biochemistry, activation, and signalling","volume":"301","author":"Grant","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bcp.2026.118500_b0075","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1111\/febs.16466","article-title":"Preferential redox regulation of cysteine-based protein tyrosine phosphatases: structural and biochemical diversity","volume":"289","author":"Netto","year":"2022","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400659","article-title":"Chemical tools for probing the Ub\/Ubl conjugation cascades","volume":"26","author":"Kocha\u0144czyk","year":"2025","journal-title":"Chembiochem"},{"issue":"12","key":"10.1016\/j.bcp.2026.118500_b0085","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1039\/D3MD00439B","article-title":"A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase","volume":"14","author":"Kuki","year":"2023","journal-title":"RSC Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor\u20051 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2026.118500_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107805","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update","volume":"217","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0100","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1039\/D1MD00068C","article-title":"Recent advances in the development of covalent inhibitors","volume":"12","author":"Kim","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0105","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","article-title":"Emerging and Re-emerging warheads for targeted covalent inhibitors: an update","volume":"67","author":"Hillebrand","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0110","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/jacs.7b08979","article-title":"Selectively targeting the kinome-conserved lysine of PI3K\u03b4 as a general approach to covalent kinase inhibition","volume":"140","author":"Dalton","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"14","key":"10.1016\/j.bcp.2026.118500_b0115","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/acs.chemrev.5c00001","article-title":"Advancing covalent ligand and drug discovery beyond cysteine","volume":"125","author":"Kim","year":"2025","journal-title":"Chem. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2026.118500_b0120","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?","volume":"10","author":"Vigil","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.bcp.2026.118500_b0135","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0140","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118500_b0145","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2021.02.002","article-title":"KRAS G12C-mutant non-small cell lung cancer: biology, developmental therapeutics, and molecular testing","volume":"23","author":"Veluswamy","year":"2021","journal-title":"J. Mol. Diagn."},{"issue":"7477","key":"10.1016\/j.bcp.2026.118500_b0150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"Pt 12","key":"10.1016\/j.bcp.2026.118500_b0155","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1107\/S2059798317015418","article-title":"Structural insight into the rearrangement of the switch I region in GTP-bound G12A K-Ras","volume":"73","author":"Xu","year":"2017","journal-title":"Acta Crystallogr D Struct Biol"},{"issue":"7781","key":"10.1016\/j.bcp.2026.118500_b0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.bcp.2026.118500_b0170","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-024-02120-6","article-title":"Fulzerasib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0175","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (Garsorasib), a potent and selective inhibitor of KRAS(G12C) in patients with NSCLC: phase 1 study results","volume":"18","author":"Li","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0185","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.11.018","article-title":"Efficacy and safety of olomorasib in combination with pembrolizumab in treatment of patients with KRAS G12C-mutant advanced NSCLC","volume":"21","author":"Burns","year":"2026","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118500_b0200","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1021\/acs.jmedchem.4c00572","article-title":"Discovery of MK-1084: an orally bioavailable and low-dose KRAS(G12C) inhibitor","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0205","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41591-025-03688-6","article-title":"D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial","volume":"31","author":"Cho","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118500_b0215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.bcp.2026.118500_b0220","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","article-title":"Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology","volume":"23","author":"J\u00e4nne","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118500_b0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1242\/jcs.1985.Supplement_3.16","article-title":"Amplification and overexpression of the EGF receptor gene in primary human glioblastomas","volume":"3","author":"Libermann","year":"1985","journal-title":"J. Cell Sci. Suppl."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0230","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.clinthera.2005.10.014","article-title":"Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Ther."},{"issue":"21","key":"10.1016\/j.bcp.2026.118500_b0235","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0240","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.bcp.2026.118500_b0245","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.bcp.2026.118500_b0250","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0255","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00210-014-0967-3","article-title":"A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer","volume":"387","author":"Modjtahedi","year":"2014","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0260","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/0008-5472.CAN-16-3404","article-title":"Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors","volume":"77","author":"Kosaka","year":"2017","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.bcp.2026.118500_b0270","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.bcp.2026.118500_b0275","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3349\/ymj.2022.63.9.799","article-title":"Lazertinib: on the way to its throne","volume":"63","author":"Lee","year":"2022","journal-title":"Yonsei Med. J."},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0280","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14656566.2022.2050213","article-title":"An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer","volume":"23","author":"Wang","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"issue":"15","key":"10.1016\/j.bcp.2026.118500_b0285","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40265-021-01588-w","article-title":"Furmonertinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0290","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2481392","article-title":"Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future","volume":"40","author":"Zhang","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem. J"},{"key":"10.1016\/j.bcp.2026.118500_b0300","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.03.015","article-title":"Targeting the fibroblast growth factor receptor family in cancer","volume":"46","author":"Hallinan","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.118500_b0305","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cytogfr.2021.09.002","article-title":"FGF\/FGFR signaling: from lung development to respiratory diseases","volume":"62","author":"Yang","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0310","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2026.118500_b0315","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","article-title":"Futibatinib: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0320","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.23433","article-title":"Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease","volume":"88","author":"Bam","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"6409","key":"10.1016\/j.bcp.2026.118500_b0325","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0330","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0335","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0340","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","article-title":"Acalabrutinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0345","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0350","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","article-title":"Tirabrutinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0355","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0360","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.118500_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101273","article-title":"BTK inhibitors resistance in B cell malignancies: mechanisms and potential therapeutic strategies","volume":"71","author":"Liu","year":"2025","journal-title":"Blood Rev."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0370","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood.2024025237","article-title":"A fresh look at covalent BTK inhibitor resistance","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0375","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New means and challenges in the targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.bcp.2026.118500_b0380","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1021\/acs.jmedchem.0c00891","article-title":"Structural basis of AZD9291 selectivity for EGFR T790M","volume":"63","author":"Yan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0385","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0390","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-Cell Receptor Signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0395","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol. Rev."},{"issue":"24","key":"10.1016\/j.bcp.2026.118500_b0400","doi-asserted-by":"crossref","first-page":"10941","DOI":"10.1128\/MCB.24.24.10941-10953.2004","article-title":"Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex","volume":"24","author":"Zhang","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118500_b0405","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"47","author":"Kensler","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0410","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","article-title":"The Nrf2 regulatory network provides an interface between redox and intermediary metabolism","volume":"39","author":"Hayes","year":"2014","journal-title":"Trends Biochem. Sci"},{"issue":"5\u20136","key":"10.1016\/j.bcp.2026.118500_b0415","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.phrs.2008.09.003","article-title":"Dual roles of Nrf2 in cancer","volume":"58","author":"Lau","year":"2008","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0420","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1158\/2159-8290.CD-21-0922","article-title":"NRF2: KEAPing tumors protected","volume":"12","author":"Pillai","year":"2022","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118500_b0430","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.jasms.2007.09.015","article-title":"Sites of alkylation of human Keap1 by natural chemoprevention agents","volume":"18","author":"Luo","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0435","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.taap.2009.06.016","article-title":"Cysteine-based regulation of the CUL3 adaptor protein Keap1","volume":"244","author":"Sekhar","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0440","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/MCB.00868-15","article-title":"Characterizations of three major cysteine sensors of keap1 in stress response","volume":"36","author":"Saito","year":"2016","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118500_b0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-025-01145-0","article-title":"Thirty years of NRF2: advances and therapeutic challenges","volume":"24","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.bcp.2026.118500_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158466","article-title":"An overview of NRF2-activating compounds bearing \u03b1,\u03b2-unsaturated moiety and their antioxidant effects","volume":"23","author":"Egbujor","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118500_b0455","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/2159-8290.CD-25-1187","article-title":"A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth","volume":"16","author":"Roy","year":"2026","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0460","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-08-0858","article-title":"Identification of nuclear export inhibitors with potent anticancer activity in vivo","volume":"69","author":"Mutka","year":"2009","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.bcp.2026.118500_b0465","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","article-title":"Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region","volume":"96","author":"Kudo","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118500_b0470","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.febslet.2004.08.056","article-title":"Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms","volume":"576","author":"Meissner","year":"2004","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0475","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","article-title":"Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1","volume":"110","author":"Sun","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0480","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0485","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-023-01649-4","article-title":"Nuclear transport proteins: structure, function, and disease relevance","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"17\u201318","key":"10.1016\/j.bcp.2026.118500_b0490","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.drudis.2013.05.005","article-title":"Parthenolide: from plant shoots to cancer roots","volume":"18","author":"Ghantous","year":"2013","journal-title":"Drug Discov. Today"},{"issue":"13","key":"10.1016\/j.bcp.2026.118500_b0495","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","article-title":"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells","volume":"110","author":"Guzman","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0500","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3892\/ijo.2020.5148","article-title":"Parthenolide inhibits the tumor characteristics of renal cell carcinoma","volume":"58","author":"Liu","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0505","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020514","article-title":"Parthenolide and its soluble analogues: multitasking compounds with antitumor properties","volume":"10","author":"Carlisi","year":"2022","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0510","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1074-5521(01)00049-7","article-title":"The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase","volume":"8","author":"Kwok","year":"2001","journal-title":"Chem. Biol."},{"issue":"43","key":"10.1016\/j.bcp.2026.118500_b0515","doi-asserted-by":"crossref","first-page":"39713","DOI":"10.1074\/jbc.M101985200","article-title":"Cysteine 38 in p65\/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones","volume":"276","author":"Garc\u00eda-Pi\u00f1eres","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0520","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.lfs.2004.01.024","article-title":"Role of cysteine residues of p65\/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential","volume":"75","author":"Garc\u00eda-Pi\u00f1eres","year":"2004","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0525","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.chembiol.2019.03.016","article-title":"Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells","volume":"26","author":"Berdan","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0530","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1074\/jbc.RA119.011396","article-title":"Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth","volume":"295","author":"Li","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0535","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41401-023-01072-z","article-title":"Investigation of targets and anticancer mechanisms of covalently acting natural products by functional proteomics","volume":"44","author":"Zhao","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0540","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40268-015-0102-z","article-title":"Molecular insight in the multifunctional effects of oridonin","volume":"15","author":"Owona","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.bcp.2026.118500_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110669","article-title":"Oridonin enhances cytotoxic activity of natural killer cells against lung cancer","volume":"122","author":"Hwang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118500_b0550","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biocel.2011.01.020","article-title":"Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics","volume":"43","author":"Li","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0555","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1021\/acs.jmedchem.6b00408","article-title":"Probing the anticancer action of oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria","volume":"59","author":"Xu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118500_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155426","article-title":"Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1","volume":"126","author":"Liu","year":"2024","journal-title":"Phytomedicine"},{"issue":"46","key":"10.1016\/j.bcp.2026.118500_b0565","doi-asserted-by":"crossref","first-page":"17471","DOI":"10.1074\/jbc.RA119.009801","article-title":"A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3","volume":"294","author":"Shen","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0570","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0575","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1631\/jzus.B1900607","article-title":"Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects","volume":"21","author":"Song","year":"2020","journal-title":"J. Zhejiang Univ. Sci. B"},{"issue":"22","key":"10.1016\/j.bcp.2026.118500_b0580","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.7150\/thno.46728","article-title":"Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0585","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-022-01231-4","article-title":"Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1","volume":"8","author":"Xu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0590","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/ars.2017.7422","article-title":"Peroxiredoxin involvement in the initiation and progression of human cancer","volume":"28","author":"Hampton","year":"2018","journal-title":"Antioxid. Redox Signal."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0595","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2015.07.002","article-title":"The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development","volume":"366","author":"Mishra","year":"2015","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0600","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s10495-011-0629-6","article-title":"Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3K\/Akt signaling pathways","volume":"16","author":"Kannaiyan","year":"2011","journal-title":"Apoptosis"},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0605","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bcp.2006.08.014","article-title":"Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid","volume":"72","author":"Lee","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118500_b0610","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.935","article-title":"Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells","volume":"8","author":"Liu","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0615","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chembiol.2018.11.013","article-title":"Frenolicin B targets peroxiredoxin 1 and glutaredoxin 3 to trigger ROS\/4E-BP1-mediated antitumor effects","volume":"26","author":"Ye","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0620","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chembiol.2023.02.003","article-title":"Ainsliadimer A induces ROS-mediated apoptosis in colorectal cancer cells via directly targeting peroxiredoxin 1 and 2","volume":"30","author":"Lv","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0625","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1142\/S0192415X15500755","article-title":"Cucurbitacins: A systematic review of the phytochemistry and anticancer activity","volume":"43","author":"Cai","year":"2015","journal-title":"Am. J. Chin. Med."},{"issue":"17","key":"10.1016\/j.bcp.2026.118500_b0630","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29174193","article-title":"Cucurbitacin B and its derivatives: a review of progress in biological activities","volume":"29","author":"Nie","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bcp.2026.118500_b0635","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/np50057a008","article-title":"Isolation of an anti-inflammatory principle from the fruit juice of Ecballium elaterium","volume":"51","author":"Yesilada","year":"1988","journal-title":"J. Nat. Prod."},{"issue":"9","key":"10.1016\/j.bcp.2026.118500_b0640","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1111\/jcmm.14514","article-title":"Cucurbitacin B induces neurogenesis in PC12 cells and protects memory in APP\/PS1 mice","volume":"23","author":"Li","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118500_b0645","first-page":"19","article-title":"Cucurbitacin B and cancer intervention: chemistry, biology and mechanisms (Review)","volume":"52","author":"Garg","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118500_b0650","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acscentsci.2c00107","article-title":"Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment","volume":"8","author":"Liu","year":"2022","journal-title":"ACS Cent. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.118500_b0655","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/j.apsb.2022.05.021","article-title":"Cucurbitacin B-induced G2\/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway","volume":"12","author":"Wei","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0660","article-title":"Ashwagandha as an adaptogenic herb: a comprehensive review of immunological and neurological effects","volume":"17","author":"Jamnekar","year":"2025","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0665","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/1566524023666230418094708","article-title":"The therapeutic effects of withaferin a against cancer: overview and updates","volume":"24","author":"Abeesh","year":"2024","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.bcp.2026.118500_b0670","doi-asserted-by":"crossref","unstructured":"P. Bargagna-Mohan, A. Hamza, Y.E. Kim, Y. Khuan Abby Ho, N. Mor-Vaknin, N. Wendschlag, J. Liu, R.M. Evans, D.M. Markovitz, C.G. Zhan, K.B. Kim, R. Mohan, The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin, Chemistry & biology 14(6) (2007) 623\u201334.","DOI":"10.1016\/j.chembiol.2007.04.010"},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0675","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.bcp.2014.08.004","article-title":"Vanden Berghe, Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKK\u03b2","volume":"91","author":"Heyninck","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118500_b0680","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chembiol.2017.08.013","article-title":"Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products","volume":"24","author":"Grossman","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118500_b0685","doi-asserted-by":"crossref","unstructured":"K. Heyninck, L. Sabbe, C.S. Chirumamilla, K. Szarc Vel Szic, P. Vander Veken, K.J.A. Lemmens, M. Lahtela-Kakkonen, S. Naulaerts, K. Op de Beeck, K. Laukens, G. Van Camp, A.R. Weseler, A. Bast, G. Haenen, G. Haegeman, W. Vanden Berghe, Withaferin A induces heme oxygenase (HO-1) expression in endothelial cells via activation of the Keap1\/Nrf2 pathway, Biochem Pharmacol 109 (2016) 48\u201361.","DOI":"10.1016\/j.bcp.2016.03.026"},{"key":"10.1016\/j.bcp.2026.118500_b0690","doi-asserted-by":"crossref","unstructured":"E. Logie, C.S. Chirumamilla, C. Perez-Novo, P. Shaw, K. Declerck, A. Palagani, S. Rangarajan, B. Cuypers, N. De Neuter, F. Mobashar Hussain Urf Turabe, N. Kumar Verma, A. Bogaerts, K. Laukens, F. Offner, P. Van Vlierberghe, X. Van Ostade, W.V. Berghe, Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells, Cancers 13(7) (2021).","DOI":"10.3390\/cancers13071618"},{"key":"10.1016\/j.bcp.2026.118500_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116405","article-title":"Covalent binding of withanolides to cysteines of protein targets","volume":"226","author":"Bailly","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118500_b0700","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.phymed.2017.07.001","article-title":"Neem (Azadirachta indica): An indian traditional panacea with modern molecular basis","volume":"34","author":"Gupta","year":"2017","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.bcp.2026.118500_b0705","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.tiv.2014.04.011","article-title":"Chemopreventive and therapeutic effects of nimbolide in cancer: the underlying mechanisms","volume":"28","author":"Bodduluru","year":"2014","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bcp.2026.118500_b0710","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.1038\/srep19819","article-title":"Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition","volume":"6","author":"Subramani","year":"2016","journal-title":"Sci. Rep."},{"issue":"46","key":"10.1016\/j.bcp.2026.118500_b0715","doi-asserted-by":"crossref","first-page":"35406","DOI":"10.1074\/jbc.M110.161984","article-title":"Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents","volume":"285","author":"Gupta","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0720","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","article-title":"Harnessing the anti-cancer natural product nimbolide for targeted protein degradation","volume":"15","author":"Spradlin","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118500_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117072","article-title":"Bis-aryl-\u03b1,\u03b2-unsaturated ketone (ABK) chaperonin inhibitors exhibit selective cytotoxicity to colorectal cancer cells that correlates with levels of aberrant HSP60 in the cytosol","volume":"75","author":"Chitre","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118500_b0730","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1124\/dmd.122.000895","article-title":"Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A","volume":"50","author":"Tang","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.bcp.2026.118500_b0735","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/jacs.4c09727","article-title":"Chemoselective stabilized triphenylphosphonium probes for capturing reactive carbonyl species and regenerating covalent inhibitors with acrylamide warheads in cellulo","volume":"147","author":"Chen","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.bcp.2026.118500_b0740","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Newlands","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118500_b0745","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/9781119847281.ch13","article-title":"Selinexor (Xpovio), an XPO1 inhibitor and A new class of therapeutics for treating multiple myeloma","author":"Mancuso","year":"2022","journal-title":"Current Drug Synthesis"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:06:28Z","timestamp":1791479188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":149,"alternative-id":["S0006295226008427"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118500","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b1,\u03b2-Unsaturated carbonyl-based anticancer agents targeting cysteine residues","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118500"}}